Simultaneous detection of multiple neuroendocrine tumor markers in patient serum with an ultrasensitive and antifouling electrochemical immunosensor

2021 ◽  
Vol 194 ◽  
pp. 113603
Author(s):  
Xuejiao Liu ◽  
Yuanliang Li ◽  
Li He ◽  
Yongjun Feng ◽  
Huangying Tan ◽  
...  
The Analyst ◽  
2012 ◽  
Vol 137 (2) ◽  
pp. 393-399 ◽  
Author(s):  
Honglan Qi ◽  
Chen Ling ◽  
Qingyun Ma ◽  
Qiang Gao ◽  
Chengxiao Zhang

2008 ◽  
Vol 54 (9) ◽  
pp. 1481-1488 ◽  
Author(s):  
Jie Wu ◽  
Feng Yan ◽  
Xiaoqing Zhang ◽  
Yuetian Yan ◽  
Jinhai Tang ◽  
...  

Abstract Background: A reagentless sensor array for simultaneous multianalyte testing (SMAT) may enable accurate diagnosis and be applicable for point-of-care testing. We developed a disposable reagentless immunosensor array for simple immunoassay of panels of tumor markers. Methods: We carried out SMAT with a direct capture format, in which colloidal gold nanoparticles with bound horseradish peroxidase (HRP)-labeled antibodies were immobilized on screen-printed carbon electrodes with biopolymer/sol-gel to trap their corresponding antigens from sample solution. Upon formation of immunocomplex, the direct electrochemical signal of the HRP decreased owing to increasing spatial blocking, and the analytes could be simultaneously determined by monitoring the signal changes. Results: The proposed reagentless immunosensor array allowed simultaneous detection of carcinoma antigen 153, carcinoma antigen 125, carbohydrate antigen 199, and carcinoembryonic antigen in clinical serum samples in the ranges of 0.4–140 kU/L, 0.5–330 kU/L, 0.8–190 kU/L, and 0.1–44 μg/L, respectively, with detection limits of 0.2 kU/L, 0.5 kU/L, 0.3 kU/L, and 0.1 μg/L corresponding to the signals 3 SD above the mean of a zero standard. The interassay imprecision of the arrays was <9.5%, and they were stable for 35 days. The positivity detection rate of panels of tumor markers was >95.5% for 95 cases of cancer-positive sera. Conclusions: The immunosensor array provides a SMAT with short analytical time, small sampling volume, no need for substrate, and, no between-electrode cross-talk. This method not only proved the capability of the array in point-of-care testing, but also allowed simultaneous testing of several tumor markers.


The Analyst ◽  
2012 ◽  
Vol 137 (20) ◽  
pp. 4727 ◽  
Author(s):  
Shenguang Ge ◽  
Feng Yu ◽  
Lei Ge ◽  
Mei Yan ◽  
Jinghua Yu ◽  
...  

2018 ◽  
Vol 10 (20) ◽  
pp. 2390-2397 ◽  
Author(s):  
Dongcheng Yang ◽  
Jing Wang ◽  
Hou Chen ◽  
Hui Xu ◽  
Wenxiang Wang ◽  
...  

A sensitive electrochemical immunosensor based on polyacrylonitrile-g-poly(hydroxyethylmethacrylate) (PAN-g-PHEMA)/graphene oxide (GO) composites was prepared for the ultrasensitive detection of tumor markers.


2007 ◽  
Vol 53 (7) ◽  
pp. 1323-1329 ◽  
Author(s):  
Dianping Tang ◽  
Ruo Yuan ◽  
Yaqin Chai

Abstract Background: Methods based on magnetic bead probes have been developed for immunoassay, but most involve complicated labeling or stripping procedures and are unsuitable for routine use. Methods: We synthesized magnet core/shell NiFe2O4/SiO2 nanoparticles and fabricated an electrochemical magnetic controlled microfluidic device for the detection of 4 tumor markers. The immunoassay system consisted of 5 working electrodes and an Ag/AgCl reference electrode integrated on a glass substrate. Each working electrode contained a different antibody immobilized on the NiFe2O4/SiO2 nanoparticle surface and was capable of measuring a specific tumor marker using noncompetitive electrochemical immunoassay. Results: Under optimal conditions, the multiplex immunoassay enabled the simultaneous detection of 4 tumor markers. The sensor detection limit was <0.5 μg/L (or <0.5 kunits/L) for most analytes. Intra- and interassay imprecisions (CVs) were <4.5% and 8.7% for analyte concentrations >5 μg/L (or >5 kunits/L), respectively. No nonspecific adsorption was observed during a series of procedures to detect target proteins, and electrochemical cross-talk (CV) between neighboring sites was <10%. Conclusion: This immunoassay system offers promise for label-free, rapid, simple, cost-effective analysis of biological samples. Importantly, the chip-based immunosensor could be suitable for use in the mass production of miniaturized lab-on-a-chip devices and open new opportunities for protein diagnostics and biosecurity.


Diabetes Care ◽  
2004 ◽  
Vol 27 (6) ◽  
pp. 1387-1393 ◽  
Author(s):  
C. E.M. De Block ◽  
G. Colpin ◽  
K. Thielemans ◽  
W. Coopmans ◽  
J. J.P.M. Bogers ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document